| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus epidermidis (SFVA-01 + methicillin-resistant) |
- |
- |
1 － ? |
Telavancin (TD-6424, Vibativ)  |
269 |
| Staphylococcus epidermidis (SFVA-01 + methicillin-resistant) |
- |
- |
2 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
269 |
| Staphylococcus epidermidis (SFVA-01 + methicillin-resistant) |
- |
- |
2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
269 |
| Staphylococcus epidermidis (SFVA-01 + methicillin-resistant) |
- |
- |
4 － ? |
Nafcillin (Unipen, Nafcil) |
269 |
| Staphylococcus epidermidis (ST277 + meticillin-resistant) |
- |
- |
1 － ? |
Daptomycin (Cubicin) |
1261 |
| Staphylococcus epidermidis (ST278 + meticillin-resistant) |
- |
- |
1 － ? |
Daptomycin (Cubicin) |
1261 |
| Staphylococcus epidermidis (SU-03 + methicillin-susceptible) |
- |
- |
0.25 － ? |
Nafcillin (Unipen, Nafcil) |
269 |
| Staphylococcus epidermidis (SU-03 + methicillin-susceptible) |
- |
- |
1 － ? |
Telavancin (TD-6424, Vibativ) |
269 |
| Staphylococcus epidermidis (SU-03 + methicillin-susceptible) |
- |
- |
2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
269 |
| Staphylococcus epidermidis (SU-03 + methicillin-susceptible) |
- |
- |
4 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
269 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
0.5 － ? |
Eperezolid (PNU-100592) |
173 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
0.5 － ? |
Eperezolid (PNU-100592) |
240 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
1 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
240 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
1 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
173 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
240 |
| Staphylococcus epidermidis (UC12084 + methicillin-resistant) |
- |
- |
2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
173 |
| Staphylococcus epidermidis (UC9912) |
- |
- |
<0.5 － ? |
Eperezolid (PNU-100592) |
240 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
0.062 |
- |
0.062 － >64 |
Rifampicin (Rifampin) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
0.25 |
- |
0.125 － 0.25 |
Fusidic acid (Fucidin) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
0.5 |
- |
0.125 － 1 |
GSQ1530 |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
2 |
- |
1 － 2 |
Linezolid (PNU-100766, U-100766, Zyvox) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
4 |
- |
0.5 － >64 |
Ofloxacin (Floxin) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
4 |
- |
4 － 16 |
Vancomycin (Vancocyn, Lyphocin) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
32 |
- |
16 － 64 |
Ampicillin (Omnipen) |
1060 |
| Staphylococcus epidermidis (vancomycin-intermediate-susceptible) |
64 |
- |
>64 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
1060 |
| Staphylococcus epidermidis (XJ75284 + methicillin-resistant) |
- |
- |
0.5 － ? |
Imipenem |
1089 |
| Staphylococcus epidermidis (XJ75284 + methicillin-resistant) |
- |
- |
8 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
1089 |
| Staphylococcus epidermidis (XJ75284 + methicillin-resistant) |
- |
- |
8 － ? |
Levofloxacin (Levaquin, Quixin) |
1089 |